Intratumoral administration of CD1c (BDCA-1) + and CD141 (BDCA-3) + myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients: a phase I clinical trial.
Julia Katharina SchwarzeJens TijtgatGil AwadaLouise CrasAngela VasaturoChristopher BagnallRamses ForsythInès DufaitSandra TuyaertsIvan Van RietBart NeynsPublished in: Journal for immunotherapy of cancer (2022)
NCT03747744.